HEALTHSTAT NEWS
From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
Biotechs are investing billions to develop a cure for alpha-1 antitrypsin deficiency (AATD), a rare liver disorder caused by a DNA mutation. The race involves U.S. and Chinese drug industries competing with dueling technologies, patent disputes, and a fractured alliance, highlighting intense global competition.
Mentioned
Related Signal
Adjacent reporting
- Targeting US$610 billion longevity market, biotech firms race to reverse ageing
- China’s biotech firms challenge US with rapidly developing RAS-targeted cancer therapies
- STAT+: Gene-editing startup launches with $230 million and a Chinese licensing deal
- Targeting US$610 billion longevity market, biotech firms race to reverse ageing
- STAT+: The China question is tearing biotech apart